The company said that Balmex is an established brand among parents with products used for diaper rash, primarily in babies and an adult line for soothing skin irritations was launched in 2013.
Moberg Pharma CEO Peter Wolpert said: "Adding Balmex to Moberg’s US portfolio is a great fit, within our core area of topical dermatology.
"We are continuously evaluating deal opportunities to further leverage our U.S. sales and marketing infrastructure.
"This deal contributes immediately to our sales and earnings and to our long term financial goal of delivering profitable growth and an EBITDA margin of 25% from 2016."
Balmex will be sold via Moberg’s existing OTC channels in US, including pharmacy chains such as CVS, Walgreens and Rite Aid as well as in mass retailers, such as Walmart and specialty retailers including Toys R’ Us and buybuyBABY.